DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/292s7p/mitochondrial) has announced the addition of the "Mitochondrial Drugs in Oncology Drug Pipeline Update 2013" report to their offering.
Focusing on mitochondria has recently become an intriguing target for cancer therapy. It is well known that mitochondrial activity in tumor cells is suppressed and exploiting the differences in mitochondrial functions between tumor and normal cells can be the key to design selective anti-cancer therapies. Compounds that directly affect mitochondrial functions are considered to present a promising alternative approach to eradicate chemotherapy-resistant cancers, as this would for an example bypass any upstream oncogenic blockade of cell death pathways.
The present drug pipeline update is focused on the different therapeutic cancer strategies addressed to target metabolic pathways or mediators of apoptosis. The first group includes drugs that act on glycolysis, ß-oxidation, electron transport chain, mitochondrial permeability and the Bcl-2/IAP family protein, the second one consists of those drugs that cause cell death through the intrinsic apoptosis pathway by promoting ROS generation or by modulating mitochondrial protein involved in apoptosis induction.
There are today 230 companies plus partners developing 241 mitochondrial drugs in oncology drugs in 848 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 131 drugs. Mitochondrial Drugs In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 177 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 175 out of the 175 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 50 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.
For more information visit http://www.researchandmarkets.com/research/292s7p/mitochondrial